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Abstract
Background
Fascioliasis and paragonimiasis are widespread foodborne trematode diseases, affecting
millions of people in more than 75 countries. The treatment of choice for these parasitic dis-
eases is based on triclabendazole, a benzimidazole derivative which has been suggested
as a promising drug to treat pregnant women and children. However, at the moment, this
drug is not approved for human use in most countries. Its potential adverse effects on em-
bryonic development have been scarcely studied, and it has not been assigned a pregnan-
cy category by the FDA. Thus, to help in the process of risk-benefit decision making upon
triclabendazole treatment during pregnancy, a better characterization of its risks during ges-
tation is needed.
Methodology
The zebrafish embryo test, a preimplantation and a postimplantation rodent whole embryo
culture were used to investigate the potential embryotoxicity/teratogenicity of triclabenda-
zole and its first metabolite triclabendazole sulfoxide. Albendazole and albendazole sulfox-
ide were included as positive controls.
Principal Findings
Triclabendazole was between 10 and 250 times less potent than albendazole in inducing
dysmorphogenic effects in zebrafish or postimplantation rodent embryos, respectively.
However, during the preimplantation period, both compounds, triclabendazole and tricla-
bendazole sulfoxide, induced a dose-dependent embryolethal effect after only 24 h of
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Conclusions/Significance
In humans, after ingestion of the recommended doses of triclabendazole to treat fascioliasis
and paragonimiasis (10 mg/kg), the main compound found in plasma is triclabendazole sulf-
oxide (maximum concentration 38.6 μM), while triclabendazole concentrations are approxi-
mately 30 times lower (1.16 μM). From our results it can be concluded that triclabendazole,
at concentrations of the same order of magnitude as the clinically relevant ones, does not
entail teratogenic potential in vitro during the organogenesis period, but its first metabolite
triclabendazole sulfoxide has a high embryotoxic capacity in vitro during the preimplantation
stage.
Introduction
Fascioliasis and paragonimiasis are food-borne trematode diseases affecting millions of people
worldwide [1]. They are acquired through ingestion of food contaminated with the larval stages
of the parasites and they affect mainly the liver and the lung, respectively. The treatment of
choice for these two parasitic diseases is based on triclabendazole (TCBZ) [2, 3, 4], a benzimid-
azole derivative active against both mature and immature flukes. Although TCBZ is only ap-
proved for veterinary use in most countries (except in Egypt, Venezuela and France where it is
also registered for human use [5, 6, 7]), it is included in the World Health Organization model
list of essential medicines for use in these two parasitic diseases [4], and it has even been sug-
gested as a promising treatment for Fasciola hepatica infections occurring in pregnant women
and children [8].
TCBZ is regarded as a safe compound during pregnancy, especially in comparison to other
benzimidazoles used to treat parasitic diseases. Most of these other benzimidazoles are terato-
genic in animals (reviewed in [9]) and have been classified within the Food and Drug Adminis-
tration (FDA) pregnancy category C (animal reproduction studies have shown an adverse
effect on the foetus and there are no adequate and well- controlled studies in humans, but po-
tential benefits may warrant use of the drug in pregnant women despite potential risks). How-
ever, this alleged safety relies on a disproportioned difference of available information among
the different benzimidazolic compounds. The developmental adverse effects of most benzimid-
azole derivatives have been comprehensively studied in vivo [10, 11, 12, 13, 14, 15] and in vitro
[16, 17, 18, 19, 20] while the adverse effects of developmental exposure to TCBZ have been
scarcely described and extrapolation from the data obtained from the other benzimidazolic
compounds is not possible since the mechanism of action of TCBZ seems to be different [21,
22]. There is a single original article available about developmental exposure to TCBZ which
describes that it has no teratogenic or embryocidal effects in rats, but the study only covers a
third part of the gestation period, leaving the initial and final developmental stages unstudied
[23]. The WHO has compiled and published a monography on this drug [24] in which the
studies on embryotoxicity and teratogenicity have been summarized. None of the studies of the
embryotoxicity and teratogenicity section (2.2.5) covers TCBZ treatment during the whole pre-
implantation period in any of the species tested (rats, rabbits, sheep and cattle). The reproduc-
tion study included (section 2.2.4), which is performed in rats, covers the preimplantation
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period, but the higher dose administered is much lower than the therapeutical doses given to
humans because the study was intended to evaluate TCBZ as a possible residue in food from
veterinary administration and not as a product directly administered to humans. Moreover, in
the revision of Hurtt [9] TCBZ was classified as fetotoxic in two species, being the rabbits more
sensitive than rats, although the original data leading to this classification is not publicly avail-
able [9]. Summarizing, there is no public information on in vitro studies covering TCBZ treat-
ment during the preimplantation period at human therapeutically relevant doses. Besides,
concerning official classifications, TCBZ has not been assigned a pregnancy category by the
FDA yet [25]. Thus, to help in the important process of risk-benefit decision making upon
TCBZ treatment during pregnancy, a better characterization of TCBZ risks during develop-
ment, and an in vivo reproduction study covering treatment during the preimplantation period
at human relevant doses, are needed.
Previous studies with other benzimidazolic compounds like albendazole (ABZ; FDA preg-
nancy category C) have shown that the parent compound exhibits more teratogenic potential
than the first sulfoxide metabolite in vitro [16, 17], while the teratogenic effects in vivomight
be mainly caused by the sulfoxide metabolite due to higher concentrations reached in plasma
and the rapid metabolism of the parent compound [16, 26, 27]. Taking this into account, the
aims of our study were: 1) to evaluate the developmental toxicity of TCBZ, 2) to study the rela-
tionship between the developmental toxic potential of the parent compound and its first me-
tabolite triclabendazole sulfoxide (TCBZSO), 3) to compare TCBZ and ABZ developmental
toxic potential, as well as that of their sulfoxide metabolites.
To address the planned objectives the developmental effects of TCBZ and TCBZSO were
tested separately using three in vitro techniques: the postimplantation whole embryo culture
(postWEC), the zebrafish embryo test (ZFET) and the preimplantation whole embryo culture
(preWEC). These techniques have been widely used for the assessment of developmental toxic-
ity [28, 29, 30, 31, 32]. They cover early developmental periods before and during the main pe-
riod of organogenesis, and they allow testing in a whole organism a parent compound and its
metabolites independently. ABZ and albendazole sufoxide (ABZSO) were used as positive con-
trols because they are well known teratogenic compounds in animals and they have been stud-
ied in vitro using the postWEC and the ZFET [16, 19, 20], thus allowing the comparison of
previous publications with the present study and with the results of TCBZ and TCBZSO. This
strategy has been used before in the study of developmental effects of other benzimidazolic
compounds [33], and avoids the bias introduced by the use of different protocols among labo-
ratories when comparing effective concentrations.
Our findings for ABZ and ABZSO correlated with the previous published results, thus con-
firming the suitability of the approach. TCBZ and TCBZSO developmental toxicity assessment
revealed no teratogenic potential for none of them, but a strong embryotoxic potential of
TCBZSO at relevant in vivo concentrations, being this effect restricted to the preimplantation
period.
Materials and Methods
Test substances
Triclabendazole, 5-chloro-6-(2,3-dichlorophenoxy)-2-(methylthio)benzimidazole, (TCBZ, =
99.7% purity, CAS number 68786-66-3) and albendazole, methyl-5-(propylthio)-2-benzimid-
azole-carbamate, (ABZ, 98% purity, CAS number 54965-21-8) were supplied by Sigma-Al-
drich Spain. Triclabendazole sulfoxide (TCBZSO,> 97% purity, CAS number 100648-13-3)
and albendazole sulfoxide (ABZSO,> 97% purity, CAS number 54029-12-8) were synthesized
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by the Organic Chemistry Laboratory from the University of Barcelona (SinteFarma UB). Both
sulfoxide metabolites were analysed and proved to be free of parent compound residues.
Animals
Sprague Dawley rats (Harlan Interfauna Iberica; Barcelona, Spain) and B6CBAF1 (C57BI/
6xCBA/J) mice (Charles River, Spain) were kept at a constant dark-light cycle of 12–12 hours
(h) and maintained at temperature of 20°C ± 2°C and humidity of 50 ± 10%. Rats and mice
were fed with 2014 Teklad Global 14% Protein Rodent Maintenance Diet (Harlan Interfauna
Iberica, Barcelona, Spain). Both received tap water ad libitum. They were monitored daily for
general health.
Adult Danio rerio zebrafish (BCN Piscicultura Iberica; Terrassa, Spain) were kept in aquari-
ums with a closed flow-through system in standardized water as specified in ISO 7346-1 and
7346-2 (ISO, 1996; 2 mM CaCl2.2H2O; 0.5 mMMgSO4.7H2O; 0.75 mM NaHCO3; 0.07 mM
KCl). Animals were maintained in an environmentally controlled room: temperature of
26 ± 1°C and constant dark-light cycle of 10–14 h respectively. Females and males were housed
separately and fed twice a day with commercial flakes (Tetramin Flakes) and with brine shrimp
to stimulate the egg production.
Ethics Statement
The postWEC and the ZFET studies were approved by the Ethic Committee for Animal Exper-
imentation of the University of Barcelona. The preWEC study was approved by the Ethics
Committee on Animal and Human Research of the Autonomous University of Barcelona. All
protocols were accepted by the Department of Environment and Housing of the Generalitat de
Catalunya with the following license numbers, postWEC: DAAM 7148, ZFET: DAAM 7971,
preWEC: DAAM 6064, and all were adhered to the Generalitat de Catalunya Decree 214/1997
of 30th of July, which regulates the use of animals for experimental and for other scientific
purposes.
Postimplantation whole embryo culture (postWEC)
Nulliparous female rats, which were checked to be in the oestrus phase of the oestrous cycle,
were housed with adult males (1:1) for 4 h, considering 2 h of light and 2 h of darkness. Mating
was confirmed by the presence of sperm in vaginal smear, and the following 24 h were consid-
ered as gestational day 0 (GD 0).
Rat embryos were explanted and evaluated as described before [34] with some variations.
Briefly, embryos were explanted at GD 9.5 under sterile conditions. Two embryos were incor-
porated in flasks filled with 3.5 mL of culture medium which contained 20% of rat serum and
80% of serum mixture (Biochrom AG; Berlin, Germany). TCBZ, TCBZSO, ABZ and ABZSO
were dissolved in dimethyl sulfoxide (DMSO; Sigma Aldrich Spain) and added to the culture
medium to a final DMSO concentration of 0.1%. Culture flasks were oxygenated at the begin-
ning of the culture with a gas mixture containing 12% O2 and after 38 h with a gas mixture con-
taining 50% O2. Embryos were cultured at a temperature of 38°C, under rotation at a speed of
25 rpm (Noria R, Ovan Spain) for 48 h. After this period, embryos presenting yolk sac circula-
tion and heartbeat were considered alive and were selected for further evaluation. The yolk sac
circulation was evaluated according to the level of formation of blood vessels, giving a score of
1 in the cases in which few vessels were observed or the vascularization was abnormal, a score
of 2 when a delay in vascularization was observed and 3 for complete vascularization, as previ-
ously described in [35]. Growth evaluation was assessed by crown-rump length and differentia-
tion was evaluated by counting the number of somites and the morphological score. This score
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is the sum of the scores given to several embryonic structures depending on their differentia-
tion stage, corresponding higher values with higher stages of differentiation [35]. Furthermore,
the percentage of dysmorphogenesis was calculated according to [36].
Zebrafish embryo test (ZFET)
The day before the test, adult male and female zebrafish were transferred (1:1) to breeding
tanks (Aquaneering, San Diego, California). Artificial plants and marbles were used as spawn-
ing substrate. Spawning and fertilization took place within 30 min after the onset of light in the
morning. Eggs were collected and extensively cleaned with ISO-standard 7346 water diluted
1:5 using deionized water. Fertilized eggs were selected under a dissection stereomicroscope
(Motic SMZ168, Motic China group, LTD., China). The eggs presenting overt anomalies like
asymmetries, formation of vesicles or damaged membranes were discarded.
Exposure and evaluation of eggs was performed as described before [32] with slight varia-
tions. At 2 hours post-fertilization (hpf) fertilized eggs were selected and transferred to 6-well
plates (Greiner Bio-one, Germany). Ten embryos were randomly distributed into wells and
filled with 5 mL of freshly prepared test solutions. TCBZ, TCBZSO, ABZ and ABZSO were dis-
solved in DMSO and subsequently diluted in 0.3x Danieau’s buffer to a final DMSO concentra-
tion of 0.05% (v/v). Embryos were incubated at 26 ± 1°C with a dark-light cycle of 10–14 h for
48 h. Embryolethality was determined at 8 hpf on the basis of egg coagulation, at 26 hpf by the
absence of tail detachment or somites formation, and at 50 hpf by the absence of heartbeat. De-
velopmental and teratogenic effects were assessed at 50 hpf by the total morphological score
described in [32].
Preimplantation whole embryo culture (preWEC)
Female mice (6–12 weeks old) were superovulated by intraperitoneal injections of 5 IU of preg-
nant mare’s serum gonadotropin (Intervet, Spain) and 5 IU of human chorionic gonadotropin
(Farma-Lepori, Spain), 48 h apart, and mated with adult males (2:1). Embryos at the one-cell
stage were obtained 24 h after the second injection by tearing the oviducts in Hepes-buffered
Chatot Ziomek Bavister medium with 150 U/ml hyaluronidase (HCZB) [37] to dissociate the
cumulus cells. Denuded embryos were then washed in HCZB and cultured for 96 h in drops of
culture medium, potassium simplex optimized medium (KSOM) [38] under oil at 37°C and
5% CO2, with or without the compounds of study. TCBZ and TCBZSO dissolved in DMSO
were diluted in KSOMmedium and the final DMSO concentration in the culture medium was
1 μM. Control embryos were cultured in the presence of 1 μMDMSO. Embryos were observed
under the stereomicroscope every 24 h to assess if they were progressing normally until the
blastocyst stage or, otherwise, they were arrested in a previous developmental stage. In each ob-
servation the number of embryos at the correct developmental stage (two-cells at 24 h, four-
cells at 48 h, morula at 72 h and blastocyst at 96 h) were counted.
Working concentrations
The working concentrations used in postWEC and ZFET techniques were selected from range-
finding experiments made for each studied compound. The ABZ and ABZSO range-finding
concentrations were chosen from previously published studies about their developmental tox-
icity [16, 19, 20] and toxicokinetics [13] as well as from studies about toxicokinetics of TCBZ
[39]. For the range finding experiments of TCBZ and TCBZSO the selected concentrations
were chosen based on the results of ABZ and ABZSO experiments, which were used in this
study as positive controls.
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For the postWEC experiments, the selected concentrations were 140 μM, 278 μM and
556 μM for TCBZ and 267 μM, 666 μM and 932 μM for TCBZSO. The tested concentrations
for ABZ analysis were 0.4 μM, 1.1 μM and 1.9 μM and for ABZSO were 3.4 μM, 9 μM, 12 μM,
14 μM and 16 μM.
The working concentrations for ZFET experiments were 0.1 μM, 0.5 μM, 1 μM, 2.5 μM and
5 μM for TCBZ studies and 0.5 μM, 1 μM, 2.5 μM, 5 μM, 10 μM and 50 μM for TCBZSO. The
experiments with ABZ were performed including concentrations of 0.025 μM, 0.05 μM,
0.1 μM, 0.3 μM and 0.5 μM and for ABZSO they included 1 μM, 6 μM, 12 μM, 25 μM and
50 μM.
TCBZ and TCBZSO concentration ranges for the preWEC study were selected based on the
results of the ZFET. The tested concentrations for this technique were 1 μM, 3 μM and 10 μM
for TCBZ studies and 3 μM, 10 μM, 30 μM and 100 μM for TCBZSO studies.
Statistics
For the postWEC and ZFET statistical analysis the StatGraphics program was used. The homo-
geneity of variances of continuous variables was assessed by the Bartlett’s test. Statistical com-
parisons of homogeneous parameters were made using a one-way analysis of variance, with the
ANOVA and the Bonferroni’s test. Statistical comparisons of non-homogeneous parameters
were made using the Kruskal-Wallis test. Categorical variables were analysed with the Fisher’s
exact test. Quantal data obtained in the preWEC experiments were analysed with the Chi-
squared test, using the GraphPad Instat program. In all statistical analyses, a probability of p<
0.05 was considered as statistically significant.
Results
Effects of TCBZ and TCBZSO in the rodent postimplantation whole
embryo culture
All embryos cultured in the postWEC study presented yolk sac circulation and heartbeat at the
end of the culture, except one embryo exposed to ABZSO 14 μM. Therefore, all cultured em-
bryos except this one were selected for further evaluation.
TCBZ exposure for 48 h at 140 μM did not produce any adverse effect in rodent GD 9.5–
11.5 embryos (Table 1). This high concentration, far above the in vivo relevant ones, was con-
sidered the highest concentration at which embryos did not present adverse effects, and was se-
lected as the no observed adverse effects concentration (NOAEC) for TCBZ in the postWEC.
At higher concentrations (up to 556 μM), TCBZ induced adverse effects in embryonic growth,
assessed by crown-rump length measurement, and in differentiation shown by somites number
and total morphological score, being the lowest observed adverse effect concentration
(LOAEC) 278 μM. These concentrations also increased the percentage of embryos presenting
at least one dysmorphic feature, reaching 100% at 556 μM. In this group of embryos the num-
ber of somites could not be determined due to widespread abnormalities (abbreviated in the
table as n.c.: not possible to count). The most observed abnormalities were in the yolk sac,
branchial bars, flexion, head and optic vesicles (S1 Table). Detailed descriptions of all abnor-
malities assessed in the postWEC are described in S2 Table.
TCBZSO did not induce any adverse effects in embryonic growth or development at
267μM. Thus, this concentration accounting for approximately seven times the in vivo relevant
concentrations in humans, was selected as the NOAEC for TCBZSO in the postWEC. The em-
bryos incubated at higher concentrations of TCBZSO (LOAEC = 666 μM) presented a dose-de-
pendent significant decrease in the total morphological score and crown-rump length
Embryotoxicity Study of Triclabendazole and Triclabendazole Sulfoxide
PLOS ONE | DOI:10.1371/journal.pone.0121308 March 20, 2015 6 / 15
(Table 1). Besides, a dose-dependent significant increase in the percentage of abnormalities
was observed. The main dysmorphogenic effects induced by TCBZSO were in the yolk sac,
branchial bars, flexion, head and optic and otic vesicles (S1 Table).
To confirm the validity of these results, and thus the absence of teratogenic potential of
TCBZ and TCBZSO in vitro, a pair of positive control compounds belonging to the same
chemical class, ABZ and ABZSO, was used for comparison. ABZ and ABZSO decreased the so-
mites number and the total morphological score and increased the percentage of dysmorpho-
genesis dose-dependently (Table 1). The LOAECs were obtained at in vivo relevant
concentrations and were as low as 1.1 and 9 μM respectively. All embryos incubated at the
highest ABZ concentration (1.9 μM) presented dysmorphogenesis, mainly in yolk sac, in bran-
chial bars, head, heart and caudal part and presence of subcutaneous blisters (S1 Table).
ABZSO exposure also produced subcutaneous blisters and a dose-dependent correlation for
branchial bars, head and caudal part dysmorphogenesis. Other main abnormalities presented
after ABZSO treatment were in the yolk sac, flexion, heart and optic and otic vesicles (S1
Table).
Summarizing the postWEC results, TCBZ and TCBZSO exposure between GD 9.5 and 11.5
did not induce adverse effects in rodent embryos until concentrations at least approximately
seven times higher than the in vivo relevant ones, indicating that these compounds have a rath-
er low teratogenic potential at in vivo relevant concentrations.
Effects of TCBZ and TCBZSO in the zebrafish embryo test
Zebrafish embryos incubated with TCBZ at 1 μM did not present any adverse effects. Higher
TCBZ exposure produced an effect on the zebrafish embryonic differentiation
Table 1. Effects of TCBZ and TCBZSO in the rodent postimplantation whole embryo culture.
E Yolk sac circulation Crown-rump length Somites number Morphological score Dysmorphogenic embryos
Median mm ± SD Mean ± SD Mean ± SD %
Control 76 3.0 3.7 ± 0.6 26.8 ± 1.9 39.1 ± 2.6 2.6
140 μM 8 3.0 3.5 ± 0.2 26.9 ± 1.1 39.0 ± 1.5 0
TCBZ 278 μM 8 1.0* 3.2 ± 0.5 25.7 ± 2.0* 35.1 ± 5.9* 62.5*
556 μM 8 1.0* 2.6 ± 0.6* n.c. 21.0 ± 3.0* 100*
267 μM 9 3.0 3.4 ± 0.4 26.6 ± 1.6 37.9 ± 2.8 0
TCBZSO 666 μM 9 3.0* 3.1 ± 0.7* 25.1 ± 2.1* 30.8 ± 7.1* 55.6*
932 μM 8 1.0* 2.3 ± 0.5* n.c. 20.3 ± 2.7* 100*
0.4 μM 8 3.0 3.5 ± 0.1 25.8 ± 1.9 38.9 ± 0.6 0
ABZ 1.1 μM 8 3.0 3.2 ± 0.2 23.9 ± 1.1* 30.8 ± 2.1* 50*
1.9 μM 8 1.0* 2.9 ± 0.4* 21.9 ± 4.5* 26.4 ± 5.2* 100*
3.4 μM 8 3.0 3.6 ± 0.2 26.9 ± 1.6 38.5 ± 2.1 12.5
9 μM 13 3.0 3.4 ± 0.3 25.0 ± 2.8 35.8 ± 5.2 30.8*
ABZSO 12 μM 10 3.0 3.6 ± 0.2 25.5 ± 2.0 38.6 ± 1.2 40*
14 μM 11 2.0* 3.4 ± 0.2 22.9 ± 1.6* 29.7 ± 6.6* 72.7*
16 μM 11 1.0* 3.1 ± 0.6* 19.3 ± 2.4* 21.8 ± 6.7* 100*
Total number of embryos (E), yolk sac circulation, crown-rump length, number of somites, total morphological score and percentage of dysmorphogenesis
obtained in each concentration group. SD: standard deviation, n.c.: not possible to count
*: p< 0.05.
doi:10.1371/journal.pone.0121308.t001
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(LOAEC = 2.5 μM), assessed by a significant decrease on the total morphological score
(Table 2). It also produced a significant increase in the percentage of embryos presenting at
least one dysmorphic feature (LOAEC = 2.5 μM). All embryos incubated with TCBZ at the
concentration of 5 μMwere dead at 50 hpf. The most observed abnormalities in zebrafish em-
bryos exposed to TCBZ are detailed in S3 Table.
TCBZSO exposure also induced an embryolethal effect at 26 hpf, but starting at 10 μM con-
centrations (LOAEC = 10 μM). None of the studied concentrations of TCBZSO decreased the
total morphological score or induced any dysmorphogenesis on the treated embryos (Table 2).
Thus, TCBZSO NOAEC was established at 5 μM.
To compare the embryotoxic potential of TCBZ and TCBZSO with previously studied com-
pounds of the same family, ABZ and ABZSO were used as positive control compounds. ABZ
and ABZSO produced a significant increase in the percentage of lethality in the higher concen-
trations, reaching 100% at 0.5 and 50 μM respectively. ABZ and ABZSO produced a significant
effect in the embryonic differentiation expressed as a decrease in the total morphological score
at the highest concentrations in which embryos were still alive, 0.3 and 25 μM respectively. At
this concentrations a significant increase in the percentage of embryos presenting
Table 2. Effects of TCBZ and TCBZSO in the zebrafish embryo test.
N E Lethality Morphological score Dysmorphogenic embryos
% Mean ± SD %
Control 14 140 5 35.9 ± 0.2 1.6
0.1 μM 3 30 0 34.8 ± 1.8 6.7
0.5 μM 3 30 0 34.8 ± 0.0 13.3
TCBZ 1 μM 3 30 0 35.8 ± 0.4 13.3
2.5 μM 3 30 0 33.0 ± 3.4* 60*
5 μM 3 30 100* n.d. n.d.
0.5 μM 3 30 17 36.0 ± 0.0 0
1 μM 3 30 10 36.0 ± 0.0 0
TCBZSO 2.5 μM 3 30 20 36.0 ± 0.0 0
5 μM 3 30 7 36.0 ± 0.0 0
10 μM 4 40 35* 36.0 ± 0.0 0
50 μM 3 30 100* n.d. n.d.
0.025 μM 3 30 7 36.0 ± 0.0 0
0.05 μM 3 30 0 35.9 ± 0.2 3.3
ABZ 0.1 μM 4 40 0 35.9 ± 0.2 2.5
0.3 μM 3 30 17* 25.5 ± 2.1* 72*
0.5 μM 3 30 100* n.d. n.d.
1 μM 3 30 0 36.0 ± 0.0 0
6 μM 3 30 0 35.7 ± 0.9 3.3
ABZSO 12 μM 3 30 0 35.5 ± 0.6 10
25 μM 3 31 13 18.0 ± 0.0* 100*
50 μM 3 30 100* n.d. n.d.
Number of independent experiments (N), total number of embryos (E), percentage of lethality, total morphological score and percentage of
dysmorphogenesis obtained in each concentration group. SD: standard deviation, n.d.: not determined
*: p< 0.05.
doi:10.1371/journal.pone.0121308.t002
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dysmorphogenesis, was also observed for both compounds, being of 100% in the case of
ABZSO (S3 Table).
To sum up, the ZFET results showed that TCBZ exposure until 50 hpf produced a signifi-
cant effect in embryonic differentiation and in lethality at concentrations 2.5 and 5 μM, respec-
tively. On the other hand, TCBZSO exposure did not produce any effects in embryonic growth
or differentiation, but produced a significant embryolethal effect during the first 24 h of expo-
sure at relevant in vivo concentrations, starting at 10 μM, and therefore rising a concern about
the embryotoxic potential of TCBZSO during the first stages of development.
Effects of TCBZ and TCBZSO in the rodent preimplantation whole
embryo culture
To confirm if embryolethal effects of TCBZSO observed in zebrafish embryos were also rele-
vant for mammalian embryos, a 96 h mouse embryo preimplantation culture, checking embry-
onic development every 24 h, was performed. In this case, the analysis of TCBZ and TCBZSO
was performed via blind studies, and ABZ and ABZSO were not used as positive controls due
to the absence of previous studies analysing the effects of these compounds during the rodent
preimplantation period in vitro.
TCBZ exposure did not produce any significant effect in preimplantation embryos at 3 μM
(Table 3). Nonetheless, it produced a significant increase in the percentage of lethality of
the highest studied concentration group (LOAEC = 10 μM), which started after only 24 h
of exposure.
TCBZSO did not induce adverse effects at 3 μM. Starting at 10 μM (LOAEC), TCBZSO pro-
duced a significant concentration-dependent lethal effect, which was already evident during
the first 24 h of exposure. At 30 μM, which is a concentration still relevant after parasitosis
treatment in humans, TCBZSO produced lethality at higher rates than 50% during the first 48
h of culture.
Consequently, the preWEC results confirmed a strong embryotoxic potential of TCBZSO
also in mammalian embryos in vitro (For a graphical overview on the results of TCBZSO in the
three in vitro techniques used, see Fig. 1).
Table 3. Effects of TCBZ and TCBZSO in the rodent preimplantation whole embryo culture.
N E 2-cells 24 h 4-cells 48 h Morula 72 h Blastocyst 96 h
% % % %
Control 4 48 2.1 4.2 6.3 22.9
1 μM 4 48 4.2 8.3 8.3 18.8
TCBZ 3 μM 4 48 6.3 6.3 10.4 20.8
10 μM 3 49 18.4* 24.5* 24.5* 36.7
3 μM 3 48 4.2 14.6 16.7 31.3
TCBZSO 10 μM 3 49 24.5* 30.6* 36.7* 55.1*
30 μM 3 49 24.5* 79.6* 95.9* 98*
100 μM 1 15 100* 100* 100* 100*
Number of independent experiments (N), total number of embryos (E), percentage of lethality in every developmental stage for each concentration group.
*: p< 0.05
doi:10.1371/journal.pone.0121308.t003
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Discussion
Fascioliasis and paragonimiasis are parasitic infections caused by flatworms or flukes. They are
classified within the foodborne trematodiases group, which is included among the major ne-
glected tropical diseases. Millions of people affected by these parasitoses are in need of effective
and safe therapies, and among them women at childbearing age represent an important portion
of population. Direct exclusion of all these women from massive treatment programs to avoid
exposure during pregnancy would prevent their access to treatment for a large proportion of
their reproductive lives. Thus, it is of uppermost importance to correctly characterize the risks
Fig 1. Graphical summary comparing TCBZSO results across species and developing time.
Representative pictures of rodent embryos exposed to increasing concentrations of TCBZSO from GD 0 to
GD 4 in the preWEC culture (LOAEClethality = 10 μM) and from GD 9.5 to GD 11.5 in the postWEC culture
(LOAECdysmorphogenesis = 666 μM). Zebrafish embryos were exposed to TCBZSO from 2 hpf to 50 hpf, a
developmental period comprising the stages covered by both rodent cultures. No dysmorphogenesis were
observed (maximum concentration tested = 50 μM), but TCBZSO was embryolethal during the first 24 h of
culture (LOAEClethality = 10 μM). Pictures correspond to the developmental time points marked in bold in the
x-axis. PreWEC embryos pictures are 10 times magnified respect to postWEC and zebrafish embryos
pictures. Scale bar: 4 mm for postWEC and zebrafish embryos; and 400 μm for preWEC embryos. ZFET:
zebrafish embryo test (concentrations = 0, 5, 10 and 50 μM); preWEC: preimplantation whole embryo
culture (concentrations = 0, 3, 10, 30 and 100 μM); postWEC: postimplantation whole embryo culture
(concentrations = 0, 27, 267 and 666 μM); GD: gestational day; hpf: hours post-fertilization.
doi:10.1371/journal.pone.0121308.g001
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associated with TCBZ treatment during pregnancy, and compile the maximum information on
concentrations of the same order of magnitude as the clinically relevant ones, to identify if
there are developmental periods where the risk associated with the exposure is lower than
in others.
In vivo, TCBZ concentrations found in plasma after its administration are very low due to
its rapid metabolism [22]. For this reason it is also important to study the effects of its main
metabolite TCBZSO, which achieves higher concentrations in plasma. For example in rabbits,
the TCBZSO maximum plasma concentration (Cmax) after a single 10 mg/kg TCBZ dose is
33 μM (transformed to μM from [40]). Apart from the data coming from laboratory animals,
several studies have evaluated the relevant concentrations after TCBZ therapeutical adminis-
tration to food producing animals and humans. In sheep, TCBZ doses of 10 mg/kg resulted in
37.26 μMCmax of TCBZSO (calculated from [41]), and in cows after a 12 mg/kg dose, the Cmax
was 71.34 μM (calculated from [39]). In humans, after a therapeutical dose of 10 mg/kg TCBZ,
the TCBZ Cmax was 1.16 μM ([42] and reviewed by [22]) and the TCBZSO Cmax was 26.6 μM
(calculated from [43]) or between 15.8 μM and 38.6 μM depending on the concomitant food
intake situation ([44] and reviewed by [22]). In vivo relevant concentrations of ABZ and
ABZSO in food producing animals and in humans have recently been reviewed by Eckardt
[16].
In our studies with rodent embryos exposed during the postimplantation period, the terato-
genic potential of TCBZ was approximately 250 times lower than the potential of ABZ
(Table 4). Both sulfoxide metabolites had less teratogenic potential than their respective parent
compounds, correlating with previous observations with other benzimidazolic derivatives [16,
17]. In this case, TCBZSO was 2.5 times less potent than its parent compound (Table 4). Even
if it occurred at very different concentration ranges, the four tested compounds induced abnor-
mal head and abnormal branchial bars in rodent embryos exposed during organogenesis.
These adverse effects are characteristic of developmental exposure to benzimidazoles, being the
second effect also representative of other azolic derivatives like triazoles [45]. Besides these al-
terations, ABZ and ABZSO exposed embryos exhibited very evident subcutaneous blisters in
the facial laterals, abnormal caudal part and abnormal heart (S1 Table). Although TCBZ and
TCBZSO have the ability of producing the same dysmorphogenesis as other compounds of
their family, these effects occur at concentrations much higher than those achieved in vivo in
Table 4. Summary of LOAEC values of rodent and zebrafish embryos exposed to TCBZ, TCBZSO, ABZ and ABZSO during 48 h in comparison to
the available in vitro and in vivo literature.
In vitro literature In vivo literature
postWEC ZFET ZFET preWEC postWEC ZFET preWEC
LOAEC
(μM)
LOAEC
dysmorphogenesis
(μM)
LOAEC
lethality
(μM)
LOAEC
(μM)
LOAEC
(μM)
LOAEC (μM) LOAEC
(μM)
Plasma concentrations
at teratogenic doses
(μM)
TCBZ 278 2.5 5 10 n.a. n.a. n.a not teratogenic at a
200mg/kg dose [23]
TCBZSO 666 not dysmorphogenic 10 10 n.a. n.a. n.a. n.a.
ABZ 1.1 0.3 0.3 n.a. 3.7 [16] 0.3 [19, 20] n.a. 0.94 ([47]; reviewed and
transformed to μM by
[13])
ABZSO 9 25 50 n.a. 17.7 [16] 6.8 [20] Non
observed adverse
effects [19]
n.a. 12.8 ([47]; reviewed and
transformed to μM by
[16])
LOAEC: lowest observed adverse effect concentration, n.a.: data not available.
doi:10.1371/journal.pone.0121308.t004
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humans after parasitosis treatment, indicating that neither TCBZ nor TCBZSO have teratogen-
ic potential at the actual recommended therapeutical doses.
The results of the zebrafish embryo test reproduced those of the postWEC concerning dys-
morphogenic potential. Again, ABZ was more potent than ABZSO at concentrations in good
agreement with the published literature (0.3 μM), and TCBZ was more potent than TCBZSO
which was not dysmorphogenic at all (Table 4). However, TCBZSO concentrations causing
embryolethality were five times lower than ABZSO concentrations killing the embryos or 2.5
times lower than concentrations producing malformations (Table 4). These results show no
dysmorphogenic activity but point to a remarkable embryotoxic potential of TCBZSO. In our
test, compound exposure started at 2 hpf, leaving the very first stages of development untreat-
ed. As previous studies observed higher sensitivity to ABZ during the first stages of develop-
ment, it cannot be excluded that TCBZSO has higher embryotoxicity when exposure starts at 0
hpf. After 48 h of exposure, the observed effects for all compounds in the zebrafish embryos
were of general toxicity, as for example cardiac oedema or decreased pigmentation and there
were no evident characteristic dysmorphogenesis for each one. Other studies working with zeb-
rafish and azolic derivatives showed that the ZFET could correctly classify the potency of the
compounds but could not reproduce the in vivo observed specific dysmorphogenesis [45].
The differences in embryolethality observed in the ZFET and the postWEC TCBZSO results
could be due to 1) inter-species differences in susceptibility to the compound or in compound
availability, or to 2) different susceptibility of the early and middle developmental periods after
exposure to TCBZSO, as the ZFET covers earlier developmental stages than the postWEC
(Fig. 1).
To distinguish between these two options, another rodent culture experiment was per-
formed with TCBZ and TCBZSO but in this case covering only the earliest period of develop-
ment (from GD 0 to GD 4). And indeed, after only 24 h of exposure TCBZSO caused a
significant increase in lethality at concentrations as low as 10 μM, thus confirming the rele-
vance of the high embryotoxic potential of TCBZSO in mammals. Previously published mecha-
nistic effects of this compound like protein synthesis inhibition or microtubule inhibition in
fluke vitelline cells [46] could be related to TCBZSO effects in preimplantation embryos, but
further studies need to be done to elucidate the exact mechanisms by which TCBZSO exerts its
embryotoxicity in mammals. Besides, studies exposing pregnant rodent dams during the pre-
implantation period are required to confirm the stage-dependent embryotoxic potential of
TCBZSO in vivo. On the other hand, TCBZ only increased lethality in preimplantation embry-
os, at concentrations 10 times higher than the in vivo relevant ones.
From our results it can be concluded that TCBZ, at concentrations of the same order of
magnitude as those achieved after intake of the recommended treatment doses for fascioliasis
and paragonimiasis, does not entail relevant dysmorphogenic potential in vitro during the or-
ganogenesis period, but its first metabolite TCBZSO has a high embryotoxic capacity in vitro
during the preimplantation stage.
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